We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Core Laboratories N.V.’s (CLB - Free Report) shares declined more than 13.5% to eventually close at $112.66 on Jul 2, after the company downwardly revised its second-quarter 2018 outlook amid deferred international activities.
In its first-quarter report, the company forecast second-quarter earnings of around 64-68 cents per share. However, a delay in the recovery of international oilfield development activities has compelled the company to cut its guidance. Hence, it now expects total revenues in the band of $174-$175 million against the prior guided range of $177-$179 million. It now anticipates EPS within 57-58 cents. However, while Core Laboratories’ second-quarter guidance has been trimmed, the revised EPS still marks year-over-year and sequential improvement.
Core Laboratories primarily operates in two principal business lines: Reservoir Description and Product Enhancement. While the company’s Product Enhancement segment will continue generating strong results, Reservoir Description will bear the brunt of reduced revenues as most (almost 85%) of the segment’s income is based on international activity levels. Delayed activities in the North Sea, Middle East and Asia-Pacific regions as well as the Gulf of Mexico will impact its revenues. Higher ramp-up costs related to deployment of new laboratory technology and infrastructure are also expected to hurt the segment’s operating income.
Further, the company anticipates sluggishness in the international activities to continue in the third quarter. However, its results are expected to start picking up from the fourth quarter.
Zacks Rank & Key Picks
Core Laboratories currently has a Zacks Rank #3 (Hold).
Some better-ranked players in the same space are China Oilfield Services Limited , Emerge Energy services LP and Archrock, Inc. (AROC - Free Report) . While China Oilfield Services sports a Zacks Rank #1 (Strong Buy), Emerge Energy and Archrock carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
China Oilfield Services’ 2018 earnings are expected to increase 5,300% year over year.
Solaris Oilfield’s earnings for 2018 are expected to increase 260.4% year over year.
Archrock’s 2018 earnings are expected to increase 210% year over year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Core Labs (CLB) Slashes Q2 Guidance, Shares Plunge 13.6%
Core Laboratories N.V.’s (CLB - Free Report) shares declined more than 13.5% to eventually close at $112.66 on Jul 2, after the company downwardly revised its second-quarter 2018 outlook amid deferred international activities.
In its first-quarter report, the company forecast second-quarter earnings of around 64-68 cents per share. However, a delay in the recovery of international oilfield development activities has compelled the company to cut its guidance. Hence, it now expects total revenues in the band of $174-$175 million against the prior guided range of $177-$179 million. It now anticipates EPS within 57-58 cents. However, while Core Laboratories’ second-quarter guidance has been trimmed, the revised EPS still marks year-over-year and sequential improvement.
Core Laboratories primarily operates in two principal business lines: Reservoir Description and Product Enhancement. While the company’s Product Enhancement segment will continue generating strong results, Reservoir Description will bear the brunt of reduced revenues as most (almost 85%) of the segment’s income is based on international activity levels. Delayed activities in the North Sea, Middle East and Asia-Pacific regions as well as the Gulf of Mexico will impact its revenues. Higher ramp-up costs related to deployment of new laboratory technology and infrastructure are also expected to hurt the segment’s operating income.
Further, the company anticipates sluggishness in the international activities to continue in the third quarter. However, its results are expected to start picking up from the fourth quarter.
Zacks Rank & Key Picks
Core Laboratories currently has a Zacks Rank #3 (Hold).
Core Laboratories N.V. Price
Core Laboratories N.V. Price | Core Laboratories N.V. Quote
Some better-ranked players in the same space are China Oilfield Services Limited , Emerge Energy services LP and Archrock, Inc. (AROC - Free Report) . While China Oilfield Services sports a Zacks Rank #1 (Strong Buy), Emerge Energy and Archrock carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
China Oilfield Services’ 2018 earnings are expected to increase 5,300% year over year.
Solaris Oilfield’s earnings for 2018 are expected to increase 260.4% year over year.
Archrock’s 2018 earnings are expected to increase 210% year over year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>